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ABSTRACT 
 
Objective: We investigated the association of anti-inflammatory cytokines interleukin-1 
receptor antagonist (IL-1ra) and adiponectin as well as pro-inflammatory cytokines IL-1ß, IL-
6, CCL2 and tumor necrosis factor (TNF)-α with ß-cell function, metabolic status and clinical 
remission in patients with recent onset type 1 diabetes. 
 
Research Design and Methods: Serum was obtained from 256 newly diagnosed patients (122 
males/ 134 females, median age 9.6 years). Stimulated C-peptide, blood glucose and HbA1c 
were determined in addition to circulating concentration of cytokines at one, six and twelve 
months after diagnosis. Analyses were adjusted for sex, age and BMI percentiles. 
 
Results: Anti-inflammatory IL-1ra was positively associated with C-peptide after six 
(p=0.0009) and twelve months (p=0.009). The beneficial association of IL-1ra on ß-cell 
function was complemented by the negative association of IL-1ß with C-peptide after one 
month (p=0.009). In contrast, anti-inflammatory adiponectin was elevated in patients with 
poor metabolic control after six and twelve months (p<0.05) and positively correlated to 
HbA1c after one month (p=0.0004). Proinflammatory IL-6 was elevated in patients with good 
metabolic control after one month (p=0.009) and showed a positive association with blood 
glucose disposal after twelve months (p=0.047). 
 
Conclusions: IL-1ra is associated with preserved ß-cell capacity in type 1 diabetes. This 
novel finding indicates that administration of IL-1ra, successfully improving ß-cell function 
in type 2 diabetes, may also be a new therapeutic approach in type 1 diabetes. The relation of 
adiponectin and IL-6 with remission and metabolic status transfers observations from in vitro 
and animal models into the human situation in vivo.  
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ype 1 diabetes is an immune-
mediated disease leading to selective 
destruction of insulin producing ß-
cells in which cytokines play an important 
role (1). Cytokines related to the innate 
immune response such as interleukin (IL)-
1ß (2-6), IL-1 receptor antagonist (IL-1ra) 
(7), monocyte chemoattractant protein 
(MCP)-1/ CCL2 (8-10), tumor necrosis 
factor (TNF)-α (2,11), IL-6 (3,12), and 
adiponectin (13,14) are thought to be 
associated with ß-cell destruction and 
disease status in humans and animal models. 
So far, no association of these markers with 
endogenous C-peptide secretion and 
metabolic status has been demonstrated in 
patients with type 1 diabetes. A recent small 
study has described slightly decreased 
circulating concentrations of IL-1ra three 
months after type 1 diabetes onset in 
patients not undergoing remission, however 
no data on C-peptide were available in these 
subjects (7).  
Type 1 and type 2 diabetes are characterized 
by progressive ß-cell failure although the 
time-courses and mechanisms by which 
cytokines and nutrients trigger ß-cell death 
seem to differ (2). Nevertheless, the immune 
response in type 2 diabetes is thought to 
play a pathogenic role for disease 
development (15) perhaps similarly but not 
identically as for type 1 diabetes. Larsen et 
al. showed that administration of exogenous 
anti-inflammatory IL-1ra in type 2 diabetes 
patients could preserve endogenous insulin 
production and attenuated inflammation 
(16). IL-1ra is the natural antagonist of IL-
1ß that induces programmed cell death 
(apoptosis) in ß-cells (17).  
Pro-inflammatory cytokines like CCL2 
and TNF-α are known to impair insulin 
signaling (18-20) and therefore it is not 
surprising that there is an association of 
cytokines with insulin resistance (21-23). 
Interestingly, adipose tissue plays an 
important role for cytokine secretion and 
may actually be a major source of pro-
inflammatory cytokines (12,23-25) but is 
also a source of IL-1ra and adiponectin, 
which display anti-inflammatory and insulin 
sensitizing effects (17,26,27). Some 
cytokines, like the pro-inflammatory IL-6 
and insulin sensitizing plus anti-
inflammatory adiponectin, affect not only 
insulin signaling but also reveal an insulin 
independent role in glucose disposal 
(27,28). 
In the current study we investigated in 
the longitudinally, prospectively performed 
Hvidøre study patients with recent onset 
type 1 diabetes. We determined how pro-
and anti-inflammatory cytokines IL-1ß, IL-
1ra, adiponectin, IL-6, CCL2 and TNF-α 
that are associated with ß-cell survival or 
insulin action, are related to endogenous ß-
cell function, metabolic control, glucose 
disposal and clinical status.  
 
RESEARCH DESIGN AND METHODS 
Subjects. Patients were recruited 
consecutively in 18 centres throughout 
Europe (n=252) and Japan (n=4) from the 
Hvidøre Study. The design and 
characteristics of the Hvidøre Study has 
been explained elsewhere (29-31). In brief, 
prospective clinical and biochemical data 
were available from diagnosis up to one 
year for 256 children and adolescents (134 
girls and 122 boys, median age 9.6 years, 
range 3 months to 16.8 years) out of 275 
initially investigated patients at baseline 
(response rate 93.1%). Only these 256 
patients entered subsequent analyses. 
Exclusion criteria were non-type-1 diabetes 
(MODY, secondary diabetes and other), or 
initial treatment outside the centres for more 
than five days. Patients were diagnosed with 
type 1 diabetes according to the World 
Health Organization (WHO) criteria (32). 
The study was performed according to the 
criteria of the Helsinki II Declaration and 
was approved by the local ethic committee 
in each centre. All patients (where 
applicable), their parents or guardians gave 
informed consent. 
Metabolic parameters. When diabetes was 
T 
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diagnosed, blood pH was determined by 
routine laboratory methods and was used to 
assess and adjust for the severity of the 
metabolic disorder (33). Body mass index 
(BMI) percentiles were used to assess the 
influence of adipose tissue which is more 
accurate in children and adolescents than the 
use of BMI alone. Stimulated serum C-
peptide as a marker of ß-cell function (34) 
was measured in a central facility at one, 
six, and twelve months after diagnosis. 
Blood samples were obtained 90 minutes 
after the ingestion of a standardized liquid 
meal (Boost drink, formerly known as 
Sustacal (237 ml or 8 FL OZ containing 33 
g carbohydrate, 15 g protein and 6 g fat, 240 
kcal): 6 ml/kg (maximum 360 ml), Novartis 
Medical Health, Inc., Minneapolis, MN, 
USA, www.boost.com). Serum samples 
were labeled and frozen at –20°C until 
shipment on dry-ice to Steno Diabetes 
Center for central determination of C-
peptide.  
Serum C-peptide was analyzed by a 
fluoroimmunometric assay 
(AutoDELFIATM C-peptide, PerkinElmer 
Life and Analytical Sciences, Inc, Turku, 
Finland). The sensitivity was below 1 
pmol/l, the intra-assay coefficient of 
variation were below 6% at 20 pmol/l, and 
recovery of the standard, added to plasma 
before extraction, was about 100% when 
corrected for losses inherent in the plasma 
extraction procedure.  
Glycemic control as assessed by HbA1c was 
measured at diagnosis and one, three, six, 
nine and twelve months after diagnosis. 
HbA1c was determined centrally by ion-
exchange high-performance liquid 
chromatography (normal reference range 
4.1-6.4 %) at Steno Diabetes Center, 
Gentofte, Denmark (31,35-37). 
We used different definitions to classify 
patients by their clinical outcome, partial 
remission and improved C-peptide 
secretion. To define remission, values of 
HbA1c and insulin requirement six months 
after diagnosis were used. First, a more 
classical definition of partial remission was 
applied, HbA1c < 7.5% and daily insulin < 
0.4 U/kg (remission 7.5) (38). However, 
partial remission discriminated by HbA1c < 
7.5% is not always indicative for a 
euglycemic status. Therefore we used in 
addition a stricter definition of partial 
remission that was HbA1c < 6.5% and daily 
insulin < 0.4 U/kg (remission 6.5). For 
determination of complete remission, 
patients would ideally not require any 
insulin, however it is recommended to 
support patients with low doses of insulin 
even in case of “complete” transient 
remission and therefore such patients were 
not available. Second, patients were 
classified according to whether C-peptide 
improved or not from one to six months 
after diagnosis with a lower limit of 100 
pmol/l. To account for interassay variation 
of C-peptide determination an increase of at 
least 20% was defined as improved C-
peptide secretion.  
The difference of blood glucose (∆blood 
glucose) was determined before and 90 
minutes after ingestion of the standardized 
liquid meal and was taken as a measure of 
blood glucose disposal. 
Cytokines and chemokines. Blood was 
drawn 90 minutes after ingestion of the 
standardized liquid meal. Serum samples 
were labeled and frozen at –20°C until 
shipment on dry ice to the German Diabetes 
Centre for determination of cytokines. 
Serum samples were measured at time 
points one, six and twelve months after 
diabetes diagnosis. Concentrations of IL-6 
and total adiponectin were measured by 
ELISA. IL-6 was determined using matched 
antibody pairs from Sanquin (PeliKine 
ELISA kit, Amsterdam, The Netherlands) as 
described (22), total adiponectin by 
commercially available kits (Quantikine, 
R&D Systems, Wiesbaden, Germany) (39). 
IL-1ß, IL-1ra, CCL2 and TNF-α were 
determined by multiplex-bead technology 
using commercially available kits 
(Fluorokine MAP, R&D Systems). All 
cytokines were measured in a blinded 
fashion, e.g. clinical data were not known 
when measurements were performed. The 
detection limits of the assays were 6.7 pg/ml 
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for adiponectin, 13.6 pg/ml for IL-1ra, 0.4 
pg/ml for IL-1ß, 0.15 pg/ml for IL-6, 1.8 
pg/ml for CCL2 and 1.35 pg/ml for TNF-α. 
Determinations of cytokine concentrations 
lower than the detection limit were assigned 
a value half of the detection limit (IL-1ra 
n=0; adiponectin n=0; IL-6 n=0; CCL2 n=0; 
TNF-α n=31). Because IL-1ß was only 
detectable in 12% (n=86) of all samples this 
cytokine was treated detectable or not 
detectable in all analyses. The 
immunoassays showed inter-assay 
variations below 20% and intra-assay 
variations below 10%. 
Statistical methods. Cytokine 
concentrations showed no Gaussian 
distribution and data are described by 
medians. Differences between cytokine 
concentrations during follow up were 
analyzed first by Friedmann test followed 
by Wilcoxon test in case of significance to 
investigate differences between two time 
points. Distribution and differences between 
follow up of IL-1ß were not investigated 
since too many values were below the 
detection limit. Log transformed cytokines 
were approximately normally distributed 
and entered Spearman correlation analysis 
to investigate correlations between 
cytokines and linear regression analysis to 
investigate associations between cytokines 
and metabolic parameters. Regression 
analysis included cytokines as the 
dependent variable and sex, age, BMI 
percentiles, blood pH, C-peptide and HbA1c 
as independent variables. Analyses 
investigating the influence of cytokines on 
∆blood glucose included cytokines as the 
dependent variable and sex, age, BMI 
percentiles and ∆blood glucose as 
independent variables. For the analysis of 
IL-1ß and metabolic parameters logistic 
regression was performed using the same 
independent variables as in the linear 
regression analysis. Associations are 
descriptive and were not corrected for 
multiple testing. Adjustment for BMI 
percentiles are based on the 2000 CDC 
growth charts (www.cdc.gov/growthcharts) 
of the Centers of Disease Control and 
Prevention, 1600 Clifton Rd, Atlanta, GA 
30333, USA. Statistical analyses were 
performed using SAS version 9.1 (SAS 
Institute, Inc., Cary, NC, USA) and 
GraphPad PRISM version 4 for Windows. 
 
RESULTS 
Longitudinal analysis of circulating 
cytokine concentrations. First we 
investigated circulating cytokines of patients 
with newly diagnosed type 1 diabetes during 
the first year after diagnosis. Circulating 
concentrations of adiponectin (p<0.0001), 
IL-6 (p=0.0008) and CCL2 (p<0.0001) were 
significantly higher one month compared to 
six and twelve months after diagnosis 
despite a large overlap between time points 
(Figure 1). TNF-α and IL-1ra did not 
statistically differ during follow-up (p=0.16 
and p=0.77, respectively), demonstrating 
that there is no general up-regulation of all 
cytokines measured one month after 
diagnosis. Because of too many values 
below detection limit differences of IL-1ß 
were not investigated.  
Associations between serum cytokines. It is 
well known, that cytokines and chemokines 
are part of a complex network. Spearman’s 
correlation analysis including all cytokines 
was performed to investigate associations 
between cytokines (Table 1). Interestingly, 
similar association patterns one and six 
months after diagnosis were seen, whereas 
twelve months after diagnosis cytokines 
seemed related less often. To our surprise, 
all statistically significant correlations 
between cytokines found were positive. 
Adiponectin was the only cytokine that 
exhibited no association at any time with the 
cytokines investigated. One month after 
diagnosis anti-inflammatory IL-1ra revealed 
associations to pro-inflammatory TNF-α, 
IL-6, CCL2 and IL-1ß (Table 1). Within the 
pro-inflammatory cytokines CCL2 was 
positively associated to TNF-α, IL-6 and IL-
1ß, and IL-6 to IL-1ß. 
Six months after diagnosis, analyses 
revealed a similar association pattern as in 
one month after diagnosis (Online appendix 
1). Twelve months after diagnosis fewer 
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associations were found (Online appendix 
2). Interestingly, the associations of anti-
inflammatory IL-1ra with IL-6, CCL2 and 
IL-1ß were maintained. 
Basic characteristics of patients classified 
by their clinical outcome. In the next step, 
we classified patients by their clinical 
outcome such as remission and improved C-
peptide secretion (Table 2). Patients with 
incomplete data record with respect to 
classification were excluded from the 
respective analyses: 22 patients missed data 
for the classification of remissions, 45 
patients had incomplete data on C-peptide 
values. At baseline, both definitions of 
remission revealed higher C-peptide and 
BMI percentiles and lower HbA1c for 
remitters in contrast to non-remitters. Non-
remitter showed lower blood pH in the 
classification of remission 7.5; for the 
stricter definition of remission 6.5, age was 
significant higher in remitters. The 
classification of improved C-peptide 
secretion revealed no significant differences. 
Association of circulating cytokines with 
clinical status. To assess the association of 
cytokines with clinical status we searched 
for a relation of circulating cytokines and 
the classification regarding clinical 
outcome. Regression analysis was applied to 
take differences of cytokine concentration 
due to age and sex differences into 
consideration. In the first approach, 
regression analysis was performed adjusting 
for sex and age; in the second approach, 
regression analysis was performed adjusting 
for sex, age and BMI percentiles since 
adipose tissue is known to be an origin of 
cytokine secretion. As before, patients with 
incomplete data record with respect to 
classification were excluded from analysis, 
22 patients for the classification of 
remissions, 45 patients for improved C-
peptide secretion. 
The first regression model revealed elevated 
anti-inflammatory IL-1ra in remitters of 
both definitions of remission compared to 
non-remitters. Furthermore, IL-1ra was also 
elevated in patients with increased C-
peptide secretion (Figure 2). 
In contrast, the anti-inflammatory 
adiponectin was lower in remitters of both 
definitions of remission but unrelated to C-
peptide classification (Figure 2). 
Interestingly, the pro-inflammatory IL-6 
was elevated in patients in remission 7.5 and 
in patients with increased C-peptide 
secretion (Figure 2). 
In the second regression model that included 
BMI percentiles as co-variable in order to 
account for the effect of cytokine secretion 
by adipose tissue we observed the same 
association for IL-1ra with increased C-
peptide one month after diagnosis (p=0.016) 
suggesting a BMI percentile independent 
association. In contrast, associations of IL-
1ra with both definitions of remission were 
lost while adjusting for BMI percentiles. 
Adiponectin showed similar associations as 
in the analysis without adjustment for BMI 
percentiles in remission 6.5 (six (p=0.037) 
and twelve months (p=0.019) after 
diagnosis). Classification of remission 7.5 
showed no association anymore to 
adiponectin. 
When adjusting for BMI percentiles, IL-6 
revealed a similar association with 
remission 7.5 one month after diagnosis 
(p=0.0097) and improved C-peptide 
secretion six (p=0.005) and twelve (p=0.03) 
months after diagnosis as in analyses 
without additional adjustment. 
Association of circulating cytokines with 
HbA1c and C-peptide. To address the 
relationship of circulating cytokines and ß-
cell function in more detail, we investigated 
the association of cytokines with ß-cell 
function measured by stimulated C-peptide 
and glycemic control determined by HbA1c. 
First, regression analysis included 
cytokines, sex, age, blood pH, C-peptide 
and HbA1c. Anti-inflammatory IL-1ra 
concentrations revealed positive 
associations with C-peptide one (regression 
coefficient (ß)=0.00024; p=0.021), six 
(ß=0.00042; p=0.0001) and twelve 
(ß=0.00031; p=0.0013) months after 
diagnosis. Anti-inflammatory adiponectin 
concentrations showed a negative 
association with C-peptide twelve (ß=-
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0.00037; p=0.0037) months after diagnosis 
and related positively with HbA1c one 
(ß=0.12; p=0.0002) months after diagnosis. 
Pro-inflammatory cytokine IL-1ß was 
negatively associated with C-peptide one 
month after diagnosis (ß=-0.0021; p=0.031). 
To account for a possible influence of 
adipose tissue, BMI percentiles were added 
to the regression analysis (Table 3). Anti-
inflammatory IL-1ra concentrations were 
associated with BMI percentiles at all time 
points investigated. IL-1ra showed similar 
associations with C-peptide as without 
adjustment for BMI percentiles suggesting 
BMI independent associations with C-
peptide six and twelve months after 
diagnosis (Table 3). Anti-inflammatory 
adiponectin was independent of BMI 
percentile and analysis revealed similar 
associations as the analysis without 
adjustment of BMI percentiles; adiponectin 
was associated with C-peptide twelve 
months after diagnosis and with HbA1c one 
month after diagnosis (Table 3). Similar to 
adiponectin, pro-inflammatory IL-1ß was 
not associated with BMI percentiles and 
revealed same association as without BMI 
percentile adjustment. IL-1ß was negatively 
associated with C-peptide one month after 
diagnosis (Table 3).  
Analyses of IL-6, CCL2 and TNF-α 
revealed no association at any time to any 
metabolic parameter. 
Association of circulating cytokines with ∆ 
blood glucose in the liquid meal test. 
Cytokines influence not only insulin 
signaling, but also reveal insulin 
independent induction of glucose disposal in 
case of IL-6 and adiponectin (27,28). To 
assess the possible influence of cytokines on 
glycemic control in our study, we 
investigated whether ∆blood glucose in the 
standardized liquid meal test (taken as a 
measure of blood glucose disposal) is 
associated with circulating cytokines 
(Figure 3). Smaller ∆blood glucose is 
suggestive of a higher glucose disposal and 
likely to reflect a more healthy status. 
Regression analysis included cytokines, ∆ 
blood glucose, sex, age and BMI 
percentiles. 
Anti-inflammatory adiponectin was 
positively associated with ∆blood glucose 
(ß=0.021; p=0.024) six months after 
diagnosis. Pro-inflammatory IL-6 and CCL2 
were negatively associated with ∆blood 
glucose twelve (ß=-0.035; p=0.047) and one 
and six months after diagnosis, respectively 
(ß=-0.021; p=0.036 and ß=-0.018; p=0.046). 
IL-1ra, IL-1ß and TNF-α showed no 
association with ∆blood glucose. 
 
DISCUSSION 
Improved ß-cell function, reduced 
insulin resistance and improved glucose 
disposal are likely candidates to affect 
remission in type 1 diabetes. All these 
processes have been shown to be influenced 
by cytokines. Pro-inflammatory IL-1ß 
induces apoptosis in insulin producing ß-
cells whereas the anti-inflammatory IL-1ra 
as the specific receptor antagonist of IL-1ß 
preserves beta-cells (16,17).  
We here show that increased IL-1ra is 
associated with improved ß-cell function 
(stimulated C-peptide) in type 1 diabetes 
patients which is in line with the protective 
effect of IL-1ra on ß-cell in patients with 
type 2 diabetes (16). We observed a positive 
association with C-peptide in the regression 
models that were adjusted for sex, age and 
blood pH. In addition, we found that IL-1ra 
was elevated in patients with improved C-
peptide secretion and in patients in 
remission 7.5. Elevated IL-1ra levels were 
also maintained at twelve months when 
more stringent criteria for remission were 
applied. Additional adjustment for BMI 
percentiles in the analyses models revealed 
a positive association of IL-1ra with BMI 
percentiles (Table 3) confirming previous 
studies and supporting adipose tissue as an 
important source of IL-1ra (40,41).  
Interestingly, IL-1ra showed a BMI 
percentile independent protective 
association with C-peptide secretion when 
we performed regression analysis 
investigating metabolic parameters or 
patients with improved C-peptide secretion. 
The significant elevation of IL-1ra in 
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patients in remission was attenuated when 
adjusting for BMI percentiles.  
Remitters according to both definitions of 
remission exhibited significantly higher 
BMI percentiles one month after diagnosis 
in contrast to non-remitters. This elevation 
of BMI percentiles in remitters may be due 
to the finding that patients with more severe 
symptoms at diagnosis including lower BMI 
and ketoacidosis have more pronounced ß-
cell destruction and are less likely to 
undergo remission during follow-up than 
children with less severe symptoms. Of 
note, we have confirmed the protective 
association of IL-1ra to ß-cell function in an 
independent cohort of 99 recent onset type 1 
diabetes patients (unpublished data C. 
Pfleger, N.Schloot). 
Since IL-1ra is antagonistic to IL-1ß, it is 
interesting to note that stimulated C-peptide 
was negatively associated with circulating 
IL-1ß. However, the interpretation of these 
data requires caution since we could detect 
IL-1ß concentration in less than 15% of 
investigated samples. 
For adiponectin, the other anti-inflammatory 
cytokine expressed by adipose tissue, we 
expected higher circulating concentrations 
in remitters compared to non-remitters, 
since it has been described that adiponectin 
leads to improved glucose homeostasis 
probably due to improved glucose disposal 
(42). However, we observed lower 
adiponectin concentrations in patients in 
remission of both definitions. We also 
observed a positive association of 
adiponectin with HbA1c, a negative 
association of adiponectin with C-peptide 
and with blood glucose disposal. Whether 
the increased adiponectin concentrations in 
patients with less endogenous C-peptide 
secretion and poorer metabolic control 
resulting in more oxidative stress reflect a 
compensatory attempt to induce glucose 
homeostasis cannot be investigated in this 
type of study. Yet, recent publications report 
an up-regulation of adiponectin during 
oxidative stress that would support our 
observation (43,44). Of note, adiponectin 
revealed no association to BMI percentiles 
in contrast to IL-1ra (Table 3), both secreted 
by adipose tissue, and was not correlated 
with the other immune mediators (Table 1). 
Both findings regarding adiponectin, 
missing association with BMI percentiles 
after multiple adjustment and lack of 
association with circulating concentrations 
of cytokines are in line with previous 
findings from a population-based study (45). 
We investigated monomeric adiponectin 
that has been described to be effective (27). 
Whether high molecular weight multimers 
of adiponectin would add or reveal different 
associations is not clear and is subject to 
debate (46). 
Increased IL-6 has been shown to be linked 
with inflammation and insulin resistance 
especially in patients with metabolic 
syndrome (22). Contrary to these findings 
we observed in our study elevated IL-6 
concentrations in patients in remission and 
patients with increased C-peptide secretion 
who are thought to be characterized by 
reduced insulin resistance and inflammation 
(47,48). The negative association of IL-6 
with ∆blood glucose found in our study that 
is suggestive of induction of blood glucose 
disposal by IL-6 might explain why we 
observed elevation of IL-6 in remission. 
This suggestion is supported by several 
studies that found induction of blood 
glucose disposal by IL-6 (12,28,49,50). To 
account for the pro-inflammatory character 
of IL-6 it is important to note that we 
observed elevated IL-6 concentrations 
during the first month after diagnosis 
suggesting pro-inflammatory processes 
around diabetes onset and a decrease during 
follow up which is in line with a previous 
study (14). 
Similar to IL-6, CCL2 was elevated one 
month after diagnosis and was associated 
with higher glucose disposal but not 
associated with disease stage as had been 
assumed previously (9). 
In an additional analysis (data not shown), 
we observed in a small subgroup of patients 
that were antibody negative higher IL-1ra 
concentrations six months after diagnosis 
(p=0.017). This result is in line with our 
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observation of preserved ß-cell function 
during high IL-1ra concentrations since 
antibody negative type 1 diabetes patients 
are believed to undergo a less aggressive 
diabetes progression (51). In addition, we 
observed a negative association of IL-6 with 
glutamic acid decarboxylase antibodies 
(GADA) one month after diagnosis 
(p=0.03).  
Certainly, it would be interesting to see 
whether genotypes that have an impact on 
diabetes are also associated with 
investigated cytokines and their relation to 
ß-cell function and metabolic status. 
However, these data were not available in 
the current study and require  future study.  
The strength of the current study is that we 
had access to a well characterized cohort 
with relatively big patients’ numbers of 
newly diagnosed patients with type 1 
diabetes that were followed prospectively 
and longitudinally for twelve months. To 
our knowledge, this is the first 
comprehensive study relating ß-cell 
secretion capacity, metabolic control and 
remission status with circulating 
concentrations of cytokines in pediatric 
patients. Potential disadvantages come from 
the multicentre design of the study that 
combines heterogeneous patient groups 
throughout Europe. However, at present it 
will be difficult to obtain equivalent patient 
numbers from one region only. Also it needs 
to be kept in mind that the results presented 
here are descriptive and the outcome of 
associations observed from metabolic data 
and peripheral blood and thereby a causal 
relationship cannot be addressed. 
Furthermore, there were no clamp studies 
performed to investigate glucose disposal 
and therefore, the here reported ∆blood 
glucose gives only an indication of the 
glucose disposal capacity. Another topic 
addresses implication of BMI percentiles. 
We applied BMI percentiles from the 
United States, although the patients 
investigated origin from different centers 
mainly in Europe. This problem of 
heterogeneity could be overcome by 
applying country specific BMI, but they 
were not available for all patients. 
We conclude that IL-1ra is associated with 
preserved ß-cell capacity in type 1 diabetes. 
This novel finding indicates that 
administration of IL-1ra (anakinra), that has 
been successfully shown to improve ß-cell 
function in patients with type 2 diabetes, 
may also be a new therapeutical approach 
for type 1 diabetes patients. The relation of 
adiponectin and IL-6 with remission and 
metabolic status in patients with type 1 
diabetes transfers observations from in vitro 
and animal models into the human situation 
in vivo.  
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TABLE 1. Correlation between cytokines during the first month after diagnosis 
IL-1ß IL-6 CCL-2 TNF-α adiponectin 
Variables 
r p r p r p r p r p 
IL-1ra 0.176  0.005 0.282 <0.0001 0.220 0.0004 0.196 0.002 0.060 0.342 
IL-1ß  0.157 0.012 0.222 0.0003 0.096 0.127 -0.01 0.874 
IL-6   0.148 0.019 0.087 0.166 0.024 0.704 
CCL-2    0.167 0.007 0.017 0.785 
TNF-α     0.098 0.118 
Given are Spearman correlation coefficients (r) and p-values. Statistical significant correlations are indicated 
bold. 
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TABLE 2: Characteristics of patients classified by remission 7.5, remission 6.5 and improved C-peptide 
secretion 
Variables/ 
Classification 
n Sex 
(m/f) 
Age 
(years) 
BMI 
percentiles 
pH HbA1c 
(%) 
C-peptide 
(pmol/l) 
Patients in 
remission 7.5 
89 41/48 9.9 
(6.7;12.5) 
71.2*** 
(45.6;87.8) 
7,390*** 
(7.350; 
7.410) 
8.5*** 
(7.6;9.3) 
522*** 
(250;818) 
Patients not in 
remission 7.5 
161 87/74 9.4 
(5.4;11.3) 
52.7 
(26.8;75.3) 
7,350 
(7.250; 
7.400) 
9.1 
(8.3;9.99) 
355 
(230;516) 
Patients in 
remission 6.5 
46 18/28 10.8* 
(7.8;13.5) 
74.4** 
(48.3;87.8) 
7,385 
(7.291; 
7.410) 
8.2*** 
(7.2;9.1) 
529* 
(226;945) 
Patients not in 
remission 6.5 
204 110/94 9.3 
(5.8;11.3) 
55.8 
(29.4;76.9) 
7,370 
(7.280; 
7.400) 
9.0 
(8.3;9.8) 
375 
(231;559) 
Patients with 
improved  
C-peptide secretion 
27 15/12 10.2 
(5.9;13.1) 
62.8 
(48.3;87.8) 
7,380 
(7.250; 
7.405) 
9.1 
(7.8;9.6) 
392 
(238;787) 
Patients without 
improved  
C-peptide secretion 
200 101/99 9.5 
(6.4;11.5) 
58.2 
(31.8;79.3) 
7,365 
(7.285; 
7.400) 
8.9 
(8.2;9.9) 
410 
(230;586) 
 
Due to incomplete data record for classification 22 patients for both definition of remission and 45 patients for 
improved C-peptide secretion were excluded from analysis. Variables are reported as median and IQR. For sex, 
absolute numbers are given. Dichotomous variables and variables with non-Gaussian distribution were 
compared within the classification using Fisher's exact test and Mann-Whitney tests, respectively. *P < 0.05, 
**P < 0.01; ***P < 0.001. Statistical significant correlations are indicated bold. Sex, age and pH have been 
determined at diagnosis, BMI percentiles, HbA1c and C-peptide one month after diagnosis.
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TABLE 3: Association between cytokines and metabolic parameters 
Sex Age (years) BMI 
percentiles 
C-peptide 
(pmol/l) 
HbA1c (%) Months 
after 
diagnosi
s 
Variables/ 
models 
ß p ß p ß p ß p ß p 
1 IL-1ra 
(pg/ml) 
-0.11 0.05
9 
-
0.01
0 
0.358 0.003
6 
0.00
1 
0.0001
1 
0.279 0.00
6 
0.788 
6 IL-1ra 
(pg/ml) 
-
0.06
2 
0.30
7 
-
0.03
8 
0.0001 0.002
7 
0.04
8 
0.0003
7 
0.000
1 
0.02
8 
0.318 
12 IL-1ra 
(pg/ml) 
-
0.10
7 
0.04
9 
-
0.02
2 
0.009 0.002
3 
0.01
9 
0.0002
6 
0.009 0.04
4 
0.046 
1 IL-1ß 
(pg/ml) 
0.52
8 
0.26
8 
0.14
5 
0.082 -
0.011
7 
0.21
0 
-
0.0026
3 
0.009 -
0.09
5 
0.639 
6 IL-1ß 
(pg/ml) 
-
0.18
9 
0.65
5 
-
0.05
4 
-0.432 0.005
0 
0.52
1 
0.0010
4 
0.146 -
0.05
7 
0.781 
12 IL-1ß 
(pg/ml) 
-
0.27
5 
0.58
9 
0.07
3 
0.390 0.005
1 
0.60
2 
-
0.0004
1 
0.665 -
0.38
4 
0.119 
1 adiponecti
n (pg/ml) 
-
0.17
2 
0.02
7 
-
0.05
8 
<0.000
1 
0.001
1 
0.44
4 
0.0000
4 
0.784 0.12
1 
0.000
4 
6 adiponecti
n (pg/ml) 
-
0.09
8 
0.16
1 
-
0.04
4 
<0.000
1 
-
0.000
2 
0.89
1 
-
0.0001
8 
0.143 0.05
1 
0.111 
12 adiponecti
n (pg/ml) 
-
0.19
7 
0.00
5 
-
0.03
5 
0.0014 0.002
2 
0.09
0 
-
0.0004
7 
0.000
4 
0.03
8 
0.182 
 
The table gives regression coefficients (ß) and p-values. Linear regression analyses were performed for IL-1ra 
and adiponectin. Cytokines entered the models as log transformed variables. Logistic regression analyses were 
applied for IL-1ß. Cytokine entered the model as detectable or not detectable. Statistical significant correlations 
are indicated bold. 
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FIGURE LEGENDS 
 
Figure 1. Circulating cytokine concentrations of patients with type 1 diabetes 1, 6 and 12 
months after diagnosis. P-values for non parametric testing for paired data (Friedman- test) 
were: adiponectin and MCP-1 (p<0.0001), IL-6 (p=0.0008), TNF-α (p=0.16) and IL-1ra 
(p=0.77). In case of significance, p-values were calculated from comparison of two time 
points that are indicated in the graph. Bars represent medians. Exact values for medians are 
depicted above the x-axis for each month and time point [pg/ml]. For IL-1ß neither medians 
nor differences were investigated because of too many values below the detection limit. 
 
Figure 2. Follow up of median circulating cytokine concentrations in patients classified by 
“remission” or “improved C-peptide secretion”. Remission 7.5 (top panel) shows data based 
on the definition of remission HbA1c < 7.5 and < 0.4U/kg daily insulin. Remission 6.5 
(medium panel) refers to the definition of remission with HbA1c < 6.5 and < 0.4U/kg daily 
insulin. Patients with improved C-peptide secretion are characterized by an increase of C-
peptide from one to six months after diagnosis of at least 20% with a lower limit of 
100pmol/l. Lines represent medians of the classified groups; dashed lines for patients in 
“remission” or “increased C-peptide secretion”, black lines for patients with “no remission”or 
“no improved C-peptide secretion”. *, P < 0.05; **, P < 0.01 adjusted for sex and age. 
 
Figure 3. Correlation of circulating cytokine concentrations with ∆blood glucose. Coefficient 
(ß) and p-values of regression line plotted are adjusted for sex, age and BMI percentile. A) 
Adiponectin vs ∆blood glucose six months after diagnosis; B) IL-6 vs ∆blood glucose twelve 
months after diagnosis.
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